Table 1 Sociodemographic and clinical characteristics of JIA patients recorded in the year 2017

No. of patients

6,297

816

2,159

3,322

Age, years

11.2 (4.2)

3.9 (1.0)

8.7 (1.7)

14.6 (1.7)

Female, no. (%)

4,248 (67.5)

618 (75.7)

1,445 (66.9)

2,185 (65.8)

BMI, kg/m2, no. (%)

 SDS

-0.02 (2.12)

-0.09 (1.14)

-0.09 (2.11)

0.04 (2.30)

 underweight

736 (11.9)

86 (10.8)

256 (12.0)

394 (12.1)

 normal weight

4,533 (73.3)

646 (81.3)

1,583 (74.3)

2,304 (70.7)

 overweight

563 (9.1)

41 (5.2)

182 (8.5)

340 (10.4)

 obesity

352 (5.7)

22 (2.8)

110 (5.2)

220 (6.8)

Disease duration, years

4.5 ± 3.7

1.5 ± 1.1

4.0 ± 2.6

5.7 ± 4.3

Age at disease onset, years

6.4 ± 4.3

2.3 ± 1.1

4.6 ± 2.7

8.8 ± 4.4

JIA category, no. (%)

 RF-positive polyarthritis

129 (2.0)

4 (0.5)

19 (0.9)

106 (3.2)

 RF-negative polyarthritis

1,277 (20.3)

166 (20.3)

449 (20.8)

662 (19.9)

 Systemic JIA

242 (3.8)

34 (4.1)

86 (4.0)

122 (3.6)

 Persistent oligoarthritis

2,698 (42.9)

505 (61.9)

1,074 (49.7)

1,119 (33.7)

 Extended oligoarthritis

721 (11.5)

66 (8.1)

259 (12.0)

396 (11.9)

 Psoriatic arthritis

296 (4.7)

21 (2.6)

78 (3.6)

197 (5.9)

 Enthesitis-related arthritis

739 (11.7)

3 (0.4)

127 (5.9)

609 (18.3)

 Unclassified JIA

195 (3.1)

17 (2.1)

67 (3.1)

111 (3.3)

 Uveitis reported, no. (%)

750 (13.2)

82 (10.6)

321 (16.3)

347 (11.9)

PGA score

1.3 (1.8)

1.7 (2.1)

1.1 (1.7)

1.3 (1.9)

cJADAS-10

4.0 (4.7)

4.5 (4.9)

3.2 (4.1)

4.4 (4.9)

Number of joints with active disease

1.0 (2.7)

1.2 (2.6)

0.7 (2.1)

1.1 (3.0)

C-HAQ total score

0.2 (0.4)

0.3 (0.5)

0.2 (0.4)

0.2 (0.4)

Patient-reported pain^a

1.9 (2.5)

1.6 (2.4)

1.4 (2.2)

2.2 (2.7)

Patient-reported overall well-being^a

1.8 (2.2)

1.7 (2.1)

1.5 (1.9)

2.1 (2.3)

Patient-reported fatigue^a

1.5 (2.4)

1.4 (2.2)

1.1 (2.0)

1.7 (2.6)

Patient's global assessement^a

2.4 (2.9)

2.9 (3.3)

2.3 (3.1)

2.3 (2.7)

Treatment in past 12 months, no. (%)

 NSAIDs

1,991 (37.5)

317 (46.6)

613 (33.7)

1,061 (37.9)

 Intra-articular GCs

677 (12.8)

149 (21.9)

235 (12.9)

293 (10.5)

 Low dose GCs (< 0.2 mg/kg)

234 (4.4)

33 (4.9)

66 (3.6)

135 (4.8)

 High dose GCs or pulse therapy

320 (5.0)

70 (10.3)

95 (5.2)

155 (5.5)

 Any conventional synthetic DMARD

2,571 (47.8)

346 (52.0)

962 (51.8)

1,263 (44.3)

 Any biologic DMARD

1,312 (24.4)

82 (12.3)

393 (21.2)

837 (29.3)

Highest parental education

 No qualification (primary education)

179 (5.2)

25 (3.4)

119 (6.1)

35 (4.7)

 Secondary education

1,780 (51.9)

351 (47.3)

1,017 (52.4)

412 (54.9)

 Higher education (Graduation)

1,473 (42.9)

366 (49.3)

804 (41.4)

303 (40.4)